|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007257,
umls-concept:C0011777,
umls-concept:C0013216,
umls-concept:C0021747,
umls-concept:C0024501,
umls-concept:C0025241,
umls-concept:C0026764,
umls-concept:C0032952,
umls-concept:C0042679,
umls-concept:C0085752,
umls-concept:C0087111,
umls-concept:C0205263,
umls-concept:C0206012,
umls-concept:C0521116,
umls-concept:C1096776,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1556085
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1991-6-13
|
|
pubmed:abstractText |
277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n = 14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-alpha maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was greater than 36 months in stage II and 11 months in stage III patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0378-584X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
458-60
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:2092283-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2092283-Carmustine,
pubmed-meshheading:2092283-Combined Modality Therapy,
pubmed-meshheading:2092283-Dexamethasone,
pubmed-meshheading:2092283-Doxorubicin,
pubmed-meshheading:2092283-Female,
pubmed-meshheading:2092283-Humans,
pubmed-meshheading:2092283-Interferon Type I,
pubmed-meshheading:2092283-Male,
pubmed-meshheading:2092283-Melphalan,
pubmed-meshheading:2092283-Multiple Myeloma,
pubmed-meshheading:2092283-Neoplasm Staging,
pubmed-meshheading:2092283-Prednisone,
pubmed-meshheading:2092283-Recombinant Proteins,
pubmed-meshheading:2092283-Vincristine
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.
|
|
pubmed:affiliation |
Abt. Immunologie und Transfusionsmedizin, Zentrum Innere Medizin und Dermatologie Med. Hochschule Hannover, FRG.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
